KLK3 and prostate cancer: Conventional blood-based biomarkers such as CA125 (ovarian cancer) and PSA (prostate cancer) remain in clinical use, yet their effectiveness for early detection is fundamentally constrained by insufficient sensitivity and specificity [8,29].